Compare MIGI & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIGI | LYRA |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.6M |
| IPO Year | 2013 | 2020 |
| Metric | MIGI | LYRA |
|---|---|---|
| Price | $2.69 | $1.30 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 46.6K | ★ 73.7K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.90 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,571,720.00 | $1,534,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $0.08 |
| 52 Week High | $15.80 | $37.50 |
| Indicator | MIGI | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 36.62 | 38.15 |
| Support Level | $0.39 | $1.21 |
| Resistance Level | $3.50 | $1.52 |
| Average True Range (ATR) | 0.25 | 0.15 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 15.12 | 62.19 |
Mawson Infrastructure Group Inc is a digital infrastructure provider with diversified operations across Cryptocurrency Mining and Digital Asset Management. Its mission is to build a bridge between the rapidly emerging digital asset industry and traditional capital markets, with a focus on shareholder returns. The Company has three primary businesses: digital currency or Bitcoin self-mining, customer co-location and related services, and energy markets. It operates in a single segment surrounding its digital currency mining operation.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.